These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19351313)

  • 1. The direct factor Xa inhibitor rivaroxaban.
    Verma AK; Brighton TA
    Med J Aust; 2009 Apr; 190(7):379-83. PubMed ID: 19351313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
    Kreutz R
    Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban, an oral direct factor Xa inhibitor.
    Piccini JP; Patel MR; Mahaffey KW; Fox KA; Califf RM
    Expert Opin Investig Drugs; 2008 Jun; 17(6):925-37. PubMed ID: 18491993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rivaroxaban: clinical pharmacology].
    Mismetti P; Laporte S
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S16-21. PubMed ID: 19185782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.
    Perzborn E; Roehrig S; Straub A; Kubitza D; Misselwitz F
    Nat Rev Drug Discov; 2011 Jan; 10(1):61-75. PubMed ID: 21164526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
    Mousa SA
    Methods Mol Biol; 2010; 663():181-201. PubMed ID: 20617418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Abrams PJ; Emerson CR
    Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
    Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
    Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban: practical considerations for ensuring safety and efficacy.
    Smythe MA; Fanikos J; Gulseth MP; Wittkowsky AK; Spinler SA; Dager WE; Nutescu EA
    Pharmacotherapy; 2013 Nov; 33(11):1223-45. PubMed ID: 23712587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral direct factor Xa inhibitor gets FDA's OK.
    Thompson CA
    Am J Health Syst Pharm; 2011 Aug; 68(16):1467. PubMed ID: 21817076
    [No Abstract]   [Full Text] [Related]  

  • 16. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.
    Burghaus R; Coboeken K; Gaub T; Kuepfer L; Sensse A; Siegmund HU; Weiss W; Mueck W; Lippert J
    PLoS One; 2011 Apr; 6(4):e17626. PubMed ID: 21526168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
    Schellong S
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):817-28. PubMed ID: 23895025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.